Practical questions about Lp(a)

Every adult, at least once in a lifetime: that is the recommendation of the 2019 ESC/EAS guidelines, the 2022 EAS consensus statement, the 2021 Canadian guidelines, the 2024 NLA update and the 2026 ACC/AHA multisociety guideline. Because plasma Lp(a) is more than 90 percent genetically determined and stable over decades, one measurement usually settles it; repeat only when a value sits close to a decision threshold, after menopause, in kidney disease, or when a new therapy is started. Cascade testing of first-degree relatives is recommended when the index value is high.

Prefer nmol/L on an isoform-insensitive assay: it counts particles, and apo(a) size varies so much between people that mass units mislead. Conversion is only approximate; a flat factor of 2.0 to 2.5 misclassifies about one in ten patients around trial thresholds, and the Copenhagen conversion formula does better (Lp(a)HORIZON screening data, 2026). Quote whatever unit the laboratory reported and do not convert for a decision if you can re-measure instead.

Risk is continuous. Common markers: below 30 mg/dL (75 nmol/L) low; 50 mg/dL (125 nmol/L) the traditional risk-enhancer threshold used by most guidelines; 70 mg/dL (about 150 nmol/L) the Lp(a)HORIZON entry level; 90 mg/dL and 175 to 200 nmol/L the entry levels of the other outcomes trials; above 180 mg/dL (about 430 nmol/L) a lifetime risk equivalent to heterozygous FH. About one in five adults is above 50 mg/dL; distributions differ by ancestry, the risk per nmol/L largely does not.

Statins do not (they raise it 8 to 20 percent), nor do ezetimibe, bempedoic acid, fibrates or omega-3 fatty acids. PCSK9 monoclonal antibodies lower it 20 to 30 percent and inclisiran about 22 percent; CETP inhibition (obicetrapib) about 37 percent; niacin about 37 percent but without outcome benefit; lipoprotein apheresis 60 to 70 percent per session. None of these is an Lp(a) therapy. What works today is intensive control of everything else, LDL-C first, because Lp(a) and LDL-C risk are independent and additive.

Four are in phase 3 outcomes trials. Pelacarsen (antisense, monthly injection): Lp(a)HORIZON, 8,323 patients, completed, result awaited; it already replaced apheresis in a phase 3 trial (2026). Olpasiran (siRNA, quarterly): OCEAN(a)-Outcomes, 7,297 patients, result 2026 to 2027, plus a primary-prevention trial to 2031. Lepodisiran (siRNA, about twice a year): ACCLAIM-Lp(a), 17,300 patients, to 2029. Muvalaplin (oral, daily): MOVE-Lp(a), 10,450 patients, to 2031. Zerlasiran (siRNA) completed phase 2 and awaits a partner for phase 3. None is approved for lowering Lp(a) as of August 2026.

Signals, not proof: in the ASPREE trial older adults with Lp(a)-raising genotypes benefited from aspirin, and in MESA aspirin users with Lp(a) above 50 mg/dL had fewer coronary events and less aortic valve calcification. Reasonable to weigh in a high-Lp(a) patient without bleeding risk, pending randomised confirmation.

Yes: LPA is the genome-wide signal for aortic valve calcification, high Lp(a) roughly triples the risk of aortic stenosis at the top of the distribution and accelerates progression once disease is present. Whether Lp(a) lowering slows the valve is a question the current trials will start to answer.

Every study on this site links to its DOI and PubMed record; the Library holds the canon and the newest publications, the Trials pages carry the ClinicalTrials.gov identifiers, and the Guidelines page links each document.